NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten public offering of 18,959,914 shares of its Class A common stock at an offering price of $9.23 per share, which is equal to the last reported sale price for Immuneering’s Class A common stock on The Nasdaq Global Market on September 24, 2025. In addition, Immuneering has granted the underwriters a 30-d ...

Question-and-Answer SessionJason GerberryBofA Securities, Research Division Imagine you're sleeping a little bit better. I know you're a little nervous about placebo effects and things like that going into the data, but now that everything is sorted out and you've got the result that you wanted. Maybe that's a good place to start is talking about that data. And if you want to maybe just contextualize that data, what it means for patients, how doctors you think will interpret the data and what that means for ...

U.S. stocks slipped on Wednesday, with the Nasdaq losing more than 75 points, or 0.3%, to close at 22,497.85. The Dow Jones Industrial Average declined 0.37% to 46,121.28, while the S&P 500 eased 0.3% to 6,637.97.These are the top stocks that gained the attention of retail traders and investors through the day:Alibaba Group Holding Ltd. BABAAlibaba’s stock surged by 8.19%, closing at $176.44. The stock reached an intraday high of $180.16 and a low of $162.80, with a 52-week range of $80.06 to $180.16. The r ...

PresentationIt is now my pleasure to turn the call over to MBX Biosciences Senior Director of Investor Relations and Communications, Jim DeNike.Ladies and gentlemen, greetings, and welcome to MBX Biosciences Conference Call. Today's call is being recorded. [Operator Instructions] As a reminder, this conference is being recorded.Jim DeNike Thanks, Rob. Good morning, and thank you for joining us this morning to review the exciting top line results from our Avail Phase II clinical trial. I'm very pleased to re ...

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 24, 2025 /PRNewswire/ -- Robbins LLPÂ reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Jasper Therapeutics, Inc. (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025. Jasper, a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ("CSU"), Chronic Inducible Urticaria ("CInd ...

Sep 24, 2025 8:00 PM Eastern Daylight Time Dr. Park CDMO Selects Thermo Fisher Scientific to Equip New Viral Vector Manufacturing Facility Share Advanced bioprocessing solutions from Thermo Fisher to support large-scale production and global access to cell and gene therapies WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that Dr. Park, an emerging viral vector contract development and manufacturing organization (CDMO) based in South Korea ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population The facility marks a cornerstone of Moderna's ten-year strategic partnership with the UK Government, designed to strengthen health resilience and drive economic growth CAMBRIDGE, MA / ACCESS Newswire / September 24, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Moderna Innovation and Technology Centre (MITC) at the H ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options Before the October 14th Deadline. If you purchased or acquired stock in Unicycive between March 29, 2024 and June 27, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 24, 2025 (GLOBE NE ...

My Sell call on Moderna ( MRNA ) in April 2025 had looked a little bold at the time, given the extent of correction and perception of lack of room to correct further. So I will takeI am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management. My focus is on equity valuation, market trends, and portfolio optimization to uncover high-growth investment opportunities. As a former Vice President at Barclays, I led teams in model validation, stress testin ...